T-Cell

UPDATE: On September 25, 2009 the FDA approved pralatrexate, trade name Folotyn, as the first and only approved therapy for relapsed or refractory peripheral T-Cell lymphoma.

A Victory for Patients « CXO Footnotes 2009

Within the T-Cell regiment there are different roles including “Killers” and “Helpers.”

Psoriasis Guru » Blog Archive » T-Cells, Psoriasis and Cellular Warfare 2009

Today, the Oncology Drug Advisory Board to the FDA recommended approval for the drug pralatrexate, a treatment for patients with relapsed or refractory peripheral T-Cell lymphoma.

A Victory for Patients « CXO Footnotes 2009

In a “warning letter” (PDF) dated Feb. 25 of last year, the FDA asked Neely to remove inaccurate claims about the effectiveness of those remedies, saying the Web site violated the Federal Food, Drug and Cosmetics Act. Herbal Hope's AIDS remedy, Immunity (PDF), had been advertised as a product “Created for HIV and AIDS patients” that “has been known to raise the T-Cell count and reduce the Viral-Load in sufferers.”

ProPublica: Authorities Pose No Obstacle to Shady AIDS Charity 2009

In effect, psoriasis inspires T-Cell regiments to make war indefinitely, producing too many helper T-Cells TH-Cells for no good reason, thus causing swelling and excessive skin production.

Psoriasis Guru » Blog Archive » T-Cells, Psoriasis and Cellular Warfare 2009

Today, the Oncology Drug Advisory Board to the FDA recommended approval for the drug pralatrexate, a treatment for patients with relapsed or refractory peripheral T-Cell lymphoma.

September « 2009 « CXO Footnotes 2009

Researchers tend to agree that psoriasis is related to misbehaving T-cells, thus, since vitamin A promotes healthy T-Cell activity, it may help to suppress psoriasis.

Psoriasis Guru » Blog Archive » Is Vitamin A an Effective Psoriasis Treatment? 2009

“I gave Liberace AIDS, and all I got was $95,000 and this lousy T-Cell count.”

MICHAEL DOUGLAS WANTS TO PLAY LIBERACE 2008

These include the need to avoid the inflammatory T-Cell response (linked to the adverse reactions to AN1792) and, instead, to elicit the anti-inflammatory B-Cell response; the mechanistic targeting of Abeta; the need to elicit an adequate immune response; transport across the blood brain barrier; improved drug discovery and better early testing and other areas.

PRWeb - Daily News Feed 2010

When a piece of cancer protein is passed to a killer T-Cell, that T-Cell will spend the rest of its days bouncing through the blood stream looking to match up that protein once more and attack.

The Earth Times Online Newspaper 2010